Piramal Pharma Limited has informed the Exchange about Completion of Acquisition
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma Limited announced that its step-down wholly owned subsidiary, Piramal Healthcare Inc., has completed the subscription of 1,903 optionally convertible redeemable preference shares in another step-down wholly owned subsidiary, PPL Pharma Inc. The total investment is valued at USD 190.3 million (approximately ₹1,626.49 crore), with each share having a face value of USD 100,000. This is a follow-up to the company's earlier intimation dated April 23, 2025. Since both entities involved are wholly owned subsidiaries of Piramal Pharma, this represents an internal capital infusion/restructuring within the group rather than a third-party deal.
This is an internal group-level capital arrangement and is not expected to have a direct material impact on minority shareholders or the stock price. It signals continued internal financial restructuring and capital deployment within the Piramal Pharma group.